التفاصيل البيبلوغرافية
| العنوان: |
Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON-SEOM registry. |
| المؤلفون: |
Arias-Martinez, Aranzazu, Martínez de Castro, Eva, Gallego, Javier, Arrazubi, Virginia, Custodio, Ana, Fernández Montes, Ana, Diez, Marc, Hernandez, Raquel, Limón, María Luisa, Cano, Juana María, Vidal-Tocino, Rosario, Macias, Ismael, Visa, Laura, Martin Richard, Marta, Sauri, Tamara, Hierro, Cinta, Gil, Mireia, Cerda, Paula, Martínez Moreno, Elia, Martínez Lago, Nieves, Mérida-García, Antonio José, Gómez González, Lucía, García Navalón, Francisco Javier, Ruiz Martín, Maribel, Marín, Gema, López-López, Flora, Ruperez Blanco, Ana Belen, Fernández, Alejandro Francisco, Jimenez-Fonseca, Paula, Carmona-Bayonas, Alberto, Alvarez-Manceñido, Felipe |
| المصدر: |
Clin Transl Oncol ; ISSN:1699-3055 ; Volume:26 ; Issue:7 |
| بيانات النشر: |
Springer |
| سنة النشر: |
2024 |
| المجموعة: |
PubMed Central (PMC) |
| مصطلحات موضوعية: |
Advanced esophagogastric cancer, Chemotherapy, Cisplatin, Fluoropyrimidine, Oxaliplatin, Survival |
| الوصف: |
The optimal chemotherapy backbone for HER2-negative advanced esophagogastric cancer, either in combination with targeted therapies or as a comparator in clinical trials, is uncertain. The subtle yet crucial differences in platinum-based regimens' safety and synergy with combination treatments need consideration. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| العلاقة: |
https://doi.org/10.1007/s12094-024-03388-6Test; https://pubmed.ncbi.nlm.nih.gov/38361134Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11178610Test/ |
| DOI: |
10.1007/s12094-024-03388-6 |
| الإتاحة: |
https://doi.org/10.1007/s12094-024-03388-6Test
https://pubmed.ncbi.nlm.nih.gov/38361134Test
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11178610Test/ |
| حقوق: |
© 2024. The Author(s). |
| رقم الانضمام: |
edsbas.609B3906 |
| قاعدة البيانات: |
BASE |
